Lumosa's Chinese partner, Shanghai Pharma, has welcomed its first patient for the Phase 2 trial of LT3001, a novel treatment for acute ischemic stroke. The first patient for the multi-center, randomized, double-blind, placebo parallel-controlled phase II clinical study evaluating the safety and effectiveness of LT3001 for injection among subjects was enrolled by Xianyang Hospital, Yan'an University on April 6. The study was led by Beijing Tiantan Hospital of Capital Medical University. Other sites in the First Hospital of Jilin University, the First Affiliated Hospital of Jinan University, Beijing Tsinghua Changgung Hospital, the First Affiliated Hospital of China Medical University, Xianyang Hospital of Yan'an University, Beipiao Central Hospital, 30 research centers, including the First Affiliated Hospital of Bengbu Medical College, Zhongnan Hospital of Wuhan University, and Pingxiang People's Hospital, were launched simultaneously.